BMY.SW down 4.40% to CHF42.54 on SIX 12 Mar 2026: Oversold bounce may offer entry

BMY.SW stock fell 4.40% to CHF42.54 at market close on 12 Mar 2026 on the SIX exchange in Switzerland, setting a clear oversold bounce setup. Volume finished at 500.00 shares, far above the 50-day average price of CHF43.75, and the move followed a gap from the previous close of CHF44.50. The stock trades at PE 15.81 with EPS 2.69, which frames valuation while traders watch a short-term rebound. We use Meyka AI real-time analysis to flag the technical and fundamental drivers behind the move.

BMY.SW stock quick snapshot

Bristol-Myers Squibb Company (BMY.SW) closed the session at CHF42.54 on SIX, down CHF1.96 versus yesterday. Market cap stands near CHF70,703,584,454.00 and shares outstanding are 1,662,049,470.00. The one-day decline pushed price toward the year low of CHF42.54, while the year high remains CHF44.75. This price action is concentrated and sharp, creating conditions for a short-term rebound if buying interest returns.

BMY.SW stock technicals and oversold bounce

Momentum shows a quick sell-off: MACD histogram is -0.07 and ATR is 0.20, implying low intraday volatility but downward momentum. Price sits below the 50-day average of CHF43.75, which marks a short-term resistance level. The drop produced a high relative volume read (relVolume 22.73), indicating outsized trading versus the average.

For an oversold bounce strategy, we watch two confirmatory signals. First, a close back above CHF43.75 on higher volume. Second, a MACD cross toward the signal line. A tight stop near CHF42.00 limits risk if the decline continues.

Meyka AI rates BMY.SW with a score out of 100 and valuation view

Meyka AI rates BMY.SW with a score out of 100: 73.74 | Grade: B+ | Suggestion: BUY. This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecast output, and analyst signals. The grade is informational and not financial advice.

On valuation, BMY.SW shows a price-to-sales ratio near 1.33, price-to-book near 3.66, and free cash flow yield around 23.08%. Debt-to-equity is high at 2.75, so capital structure risk remains relevant for longer holds.

Earnings, forecasts and realistic price targets for BMY.SW stock

The next earnings announcement is set for 30 Apr 2026. Recent trailing EPS is 2.69, and forward catalysts include clinical readouts and product sales for Eliquis and oncology franchises. Meyka AI’s yearly model shows a near-term projection of CHF39.34, below current price levels.

We set practical targets for an oversold bounce: a conservative short-term target at CHF43.75, a base target at CHF46.00, and a bullish scenario near the year high CHF44.75 if momentum returns. Use the model projection as a guide, not a guarantee.

BMY.SW stock risks, sector context and catalysts

Key risks include high leverage with debt-to-equity 2.75, patent cliffs, and pipeline setbacks. Healthcare sector peers trade at higher average PE near 29.52, so BMY.SW’s PE 15.81 signals relative value but also company-specific risk. The global Healthcare sector had a 3-month performance of -1.73%, which can mute rebounds.

Catalysts that would support a sustained bounce include an upbeat April earnings report, positive trial updates, or resumed demand for Eliquis. Watch sector flows and news for sudden sentiment shifts.

Trading strategy for an oversold bounce in BMY.SW stock

We recommend a measured trading plan for an oversold bounce. Enter a staggered long in small tranches between CHF42.50 and CHF43.75 with a tight stop near CHF42.00. Scale out at CHF43.75 and CHF46.00 to lock gains. Monitor volume and MACD for confirmation before adding size.

For investors, a conviction buy requires resolving leverage concerns and clearer growth signals. Keep position sizing small given volatility and high relative volume today.

Final Thoughts

BMY.SW stock closed at CHF42.54 on 12 Mar 2026, down 4.40%, creating a textbook oversold bounce setup on the SIX market in Switzerland. Short-term traders can watch for a recovery above CHF43.75 and MACD support to confirm a bounce. Meyka AI’s forecast model projects CHF39.34, which implies -7.53% versus the current price CHF42.54, so we balance a tactical long with caution. Realistic targets: CHF43.75 (first), CHF46.00 (base), and CHF44.75 (year high resistance). Our Meyka grade of B+ signals relative opportunity but also flags capital structure risk. Use tight stops and confirm with volume and earnings updates before adding exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.